22nd Century to Present to Institutional Investors at the Citi 2018 Small & Mid Cap Conference
June 04 2018 - 09:45AM
Business Wire
22nd Century Group, Inc. (NYSE American: XXII), a plant
biotechnology company that is focused on tobacco harm reduction,
Very Low Nicotine tobacco, and hemp/cannabis research, today
announced that the Company will present at the Citi 2018 Small
& Mid Cap Conference at the Lotte New York Palace Hotel, New
York, NY on Wednesday, June 6, 2018 at 8:00AM Eastern Time.
Henry Sicignano III, President and Chief Executive Officer of
22nd Century Group, will deliver a formal presentation to
institutional investors and will discuss the Company’s recent
business highlights and updates. Mr. Sicignano will also be
available for one-on-one meetings with investors at the
conference.
The Citi Small & Mid Cap Conference is an invitation-only
event for select small-cap and mid-cap public companies. To
schedule a one-on-one meeting with Mr. Sicignano, investors should
contact:
IRTH Communications866-976-4784xxii@irthcommunications.com
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on
technology which allows it to increase or decrease the level of
nicotine in tobacco plants and the level of cannabinoids in
hemp/cannabis plants through genetic engineering and plant
breeding.
22nd Century is at the center of an intense, worldwide
scientific and regulatory movement in support of the Company’s
long-standing mission: to reduce the harm caused by smoking. 22nd
Century is the only company in the world that has grown commercial
crops of proprietary VLNTM tobacco with nicotine content of just
0.4mg per gram of tobacco – at least 95% lower nicotine content
than tobacco used in conventional cigarettes. Numerous independent
clinical trials using 22nd Century’s proprietary SPECTRUM® research
cigarettes – containing VLNTM tobacco – have shown that Very Low
Nicotine content cigarettes reduce cravings, reduce consumption of
cigarettes, and increase quit attempts.
In 2017, the U.S. Food and Drug Administration (FDA) announced a
plan to enact a reduced nicotine mandate that will require that all
cigarettes sold in the United States contain only Very Low
Nicotine content tobacco with “minimally or non-addictive levels of
nicotine.” At the same time, 22nd Century is preparing a revised
Modified Risk Tobacco Product (MRTP) application to be submitted to
the FDA in order for 22nd Century to become the first – and
potentially the only – company to receive an MRTP marketing order
from the FDA for a combustible cigarette.
Visit www.xxiicentury.com and www.botanicalgenetics.com for more
information.
Cautionary Note Regarding Forward-Looking Statements: This press
release contains forward-looking information, including all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of 22nd Century Group, Inc.,
its directors or its officers with respect to the contents of this
press release, including but not limited to our future revenue
expectations. The words “may,” “would,” “will,” “expect,”
“estimate,” “anticipate,” “believe,” “intend” and similar
expressions and variations thereof are intended to identify
forward-looking statements. We cannot guarantee future results,
levels of activity or performance. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances, or to reflect the occurrence of unanticipated
events. You should carefully review and consider the various
disclosures made by us in our annual report on Form 10-K for the
fiscal year ended December 31, 2017, filed on March 7, 2018,
including the section entitled “Risk Factors,” and our other
reports filed with the U.S. Securities and Exchange Commission
which attempt to advise interested parties of the risks and factors
that may affect our business, financial condition, results of
operation and cash flows. If one or more of these risks or
uncertainties materialize, or if the underlying assumptions prove
incorrect, our actual results may vary materially from those
expected or projected.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180604005321/en/
22nd Century GroupJames Vail, 716-270-1523Director of
Communicationsjvail@xxiicentury.com
22nd Century (AMEX:XXII)
Historical Stock Chart
From Feb 2024 to Mar 2024
22nd Century (AMEX:XXII)
Historical Stock Chart
From Mar 2023 to Mar 2024